Company Overview and News

 
ERA approves Pilbara power line

40m businessnews.com.au
Alinta has received regulatory approval to build a transmission line linking the Roy Hill mine to Fortescue Metals Group’s Cloudbreak and Christmas Creek mines, a move that would enable the iron ore miner to continue its shift away from diesel power.
FSUMF FMG FSUGY

2
Australian share market records second worst day of year as it sheds around $40 billion

2018-10-11 perthnow.com.au
ALL that glittered on Australian markets was gold as the ASX ended its second worst day of the year shedding more than $40 billion after a "perfect storm" on Wall Street caused heavy stock losses across every other sector.
RTPPF RIO RIO FSUMF RIO RTNTF SBM FMG FSUGY

2
$50b wiped from Australian share market

2018-10-11 ntnews.com.au
US markets posted some of the worst losses of the year, with the Dow Jones, S&P500 and Nasdaq down by more than 3%. Investors remain concerned about lifting US interest rates and signs some American companies are experiencing higher costs as the trade dispute with China continues. Aussie stocks are set for a fall of around 1.8% on Thursday.
RIO RIO CHEOY FSUGY RTPPF NDAQ FSUMF RIO KORS RTNTF SBM CHEOF FMG

2
When Will China Use Less Iron Ore? Not Yet

2018-10-10 seekingalpha
China is likely to continue buying the same amount of iron ore if not more from overseas iron ore miners until 2020.
RTPPF RIO RIO FSUMF RIO VALE3 RTNTF FMG FSUGY

2
Hancock secures compulsory takeover of Atlas Iron in Rinehart win

2018-10-10 australianmining.com.au
Hancock Prospecting subsidiary Redstone Corporation has secured over 90 per cent of Atlas Iron’s shares, allowing the Gina Rinehart-owned company to commence a compulsory acquisition of the junior iron ore company.
RIO RIO AGODY MALRY MIN FSUGY RTPPF AGO FSUMF RIO ATLGF RTNTF FMG MALRF

 
WA mining: Iron ore shipments from Port Hedland to China increase

2018-10-10 perthnow.com.au
IRON ore shipments to China from Port Hedland rose 5.3 per cent in September from a month earlier.
BLT FSUMF BHP BHPBF BBL BHP FMG BHPLF FSUGY

 
Paris nonstop flight on Perth airport agenda

2018-10-05 perthnow.com.au
HOPES are high that a deal will be struck between Qantas and Perth Airport over terminal use that will green light a Perth to Paris nonstop flight by late next year after the airport confirmed a top-level meeting in Sydney in the next two weeks.
FSUMF FMG FSUGY

 
National Plant & Equipment deliver Liebherr R 996B Excavator to Fortescue’s Christmas Creek Mine

2018-10-04 australianmining.com.au
National Group’s premier brand; National Plant & Equipment (NPE), has delivered the first of their two new Liebherr R 996B Excavators to Fortescue Metals Group’s (Fortescue) Christmas Creek site.
FSUMF FMG FSUGY

2
ASX closes higher on gold miners

2018-10-03 theage.com.au
Australian shares closed the session higher, ending a poor start to the week's trading, as the major material stocks led the market gains.
NCMGF NCM RIO BLT RIO EVN SCEXF NST IGO RSG RTPPF RMGGF RTNTF IOOFY SBM CAHPF FMG MS BHPBF IFL IIDDY FSUGY NESRF IOOFF NCMGY FSUMF RMGGY BHP RIO BBL BHP NHRNY BHPLF SAR

2
ASX closes higher on gold miners

2018-10-03 watoday.com.au
Australian shares closed the session higher, ending a poor start to the week's trading, as the major material stocks led the market gains.
NCMGF NCM RIO BLT RIO EVN SCEXF NST IGO RSG RTPPF RMGGF RTNTF IOOFY SBM CAHPF FMG MS BHPBF IFL IIDDY FSUGY NESRF IOOFF NCMGY FSUMF RMGGY BHP RIO BBL BHP NHRNY BHPLF SAR

2
ASX closes higher on gold miners

2018-10-03 smh.com.au
Australian shares closed the session higher, ending a poor start to the week's trading, as the major material stocks led the market gains.
NCMGF NCM RIO BLT RIO EVN SCEXF NST IGO RSG RTPPF RMGGF RTNTF IOOFY SBM CAHPF FMG MS BHPBF IFL IIDDY FSUGY NESRF IOOFF NCMGY FSUMF RMGGY BHP RIO BBL BHP NHRNY BHPLF SAR

2
Civmec secures Roy Hill, Rio Tinto contracts

2018-10-01 australianmining.com.au
Civmec’s focus on strengthening its maintenance service offering has paid off with the award of contracts from a number of leading Australian mining companies.
RTPPF RIO RIO FSUMF RIO RTNTF FMG FSUGY

2
Pilbara mine investment to create hundreds of jobs

2018-10-01 theage.com.au
About 1200 new Pilbara construction jobs are expected after Rio Tinto and its Robe River joint-venture partners announced a $US1.55 billion ($2.14 billion) investment at two ageing iron ore mines.
RTPPF RIO RIO FSUMF RIO RTNTF FMG FSUGY

2
Pilbara mine investment to create hundreds of jobs

2018-10-01 watoday.com.au
About 1200 new Pilbara construction jobs are expected after Rio Tinto and its Robe River joint-venture partners announced a $US1.55 billion ($2.14 billion) investment at two ageing iron ore mines.
RTPPF RIO RIO FSUMF RIO RTNTF FMG FSUGY

2
Pilbara mine investment to create hundreds of jobs

2018-10-01 smh.com.au
About 1200 new Pilbara construction jobs are expected after Rio Tinto and its Robe River joint-venture partners announced a $US1.55 billion ($2.14 billion) investment at two ageing iron ore mines.
RTPPF RIO RIO FSUMF RIO RTNTF FMG FSUGY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...